Core Viewpoint - The company EPS Creative Technology (03860) has signed a memorandum of understanding to acquire a 16.23% stake in China Gene Engineering Co., Ltd. from Hongshida Medical Co., Ltd. for approximately HKD 40 million to HKD 45 million, which is seen as a strategic investment to enhance its involvement in the healthcare sector and create long-term value [1][1][1] Group 1 - The acquisition involves China Gene Engineering, a Hong Kong-registered company that holds about 67.68% of Shanghai Huaxin Bio-Technology Co., Ltd. [1] - The transaction is expected to complement the company's existing businesses in healthcare product trading, medical device leasing, and providing professional contract research organization (CRO) services [1][1] - Upon completion, the investment in China Gene will be recognized as an investment in an associate company in the group's consolidated financial statements [1]
EPS创健科技(03860)拟收购中国基因16.23%股权